Results 61 to 70 of about 183,390 (190)

Systemic inflammation and residual viraemia in HIV-positive adults on protease inhibitor monotherapy: a cross-sectional study. [PDF]

, 2015
Increased levels of markers of systemic inflammation have been associated with serious non-AIDS events even in patients on fully suppressive antiretroviral therapy.
Arenas-Pinto, A, Gilson, R, Maini, M, McKendry, A, Milinkovic, A, Peppa, D   +5 more
core   +1 more source

A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency

eLife, 2017
Antiretroviral therapy for HIV-1 infection/AIDS has significantly extended the life expectancy of HIV-1-infected individuals and reduced HIV-1 transmission at very high rates.
Manabu Aoki, Hironori Hayashi, Kalapala Venkateswara Rao, Debananda Das, Nobuyo Higashi-Kuwata, Haydar Bulut, Hiromi Aoki-Ogata, Yuki Takamatsu, Ravikiran S Yedidi, David A Davis, Shin-ichiro Hattori, Noriko Nishida, Kazuya Hasegawa, Nobutoki Takamune, Prasanth R Nyalapatla, Heather L Osswald, Hirofumi Jono, Hideyuki Saito, Robert Yarchoan, Shogo Misumi, Arun K Ghosh, Hiroaki Mitsuya   +21 more
doaj   +1 more source

The initial step in human immunodeficiency virus type 1 GagProPol processing can be regulated by reversible oxidation. [PDF]

PLoS ONE, 2010
BackgroundMaturation of human immunodeficiency virus type 1 (HIV-1) occurs upon activation of HIV-1 protease embedded within GagProPol precursors and cleavage of Gag and GagProPol polyproteins.
Sarah I Daniels, David A Davis, Erin E Soule, Stephen J Stahl, Irene R Tebbs, Paul Wingfield, Robert Yarchoan   +6 more
doaj   +1 more source

Mechanism and Kinetics of HIV-1 Protease Activation

Viruses
The HIV-1 protease is a critical enzyme for viral replication. Because protease activity is necessary to generate mature infectious virions, it is a primary target of antiretroviral treatment.
Caroline O. Tabler, John C. Tilton
doaj   +1 more source

Dynamozones are the most obvious sign of the evolution of conformational dynamics in HIV-1 protease

Scientific Reports, 2023
Proteins are not static but are flexible molecules that can adopt many different conformations. The HIV-1 protease is an important target for the development of therapies to treat AIDS, due to its critical role in the viral life cycle.
Mohammad Rahimi, Majid Taghdir, Farzane Abasi Joozdani   +2 more
doaj   +1 more source

Developing HIV-1 Protease inhibitors through stereospecific reactions in protein crystals [PDF]

, 2016
Protease inhibitors are key components in the chemotherapy of HIV infection. However, the appearance of viral mutants routinely compromises their clinical efficacy, creating a constant need for new and more potent inhibitors.
De Zorzi, Rita, Demitri, Nicola, Geremia, Silvano, Olajuyigbe, Folasade M.   +3 more
core   +2 more sources

Extracellular binding of indinavir to matrix metalloproteinase-2 and the alpha-7-nicotinic acetylcholine receptor: implications for use in cancer treatment

Heliyon, 2019
Introduction: Results from recent studies have suggested a role for protease inhibitors in altering mechanisms involved in the initiation and proliferation of cancer cells.
Anna Lee, Erin Saito, Sean Ekins, Aaron McMurtray   +3 more
doaj   +1 more source

THE DESIGN, MODELING AND EVALUATION OF POTENTIAL HIV PROTEASE INHIBITORS USING BLITZ, AN INTERACTIVE COMPUTER GRAPHICS WORKING TOOL [PDF]

Journal of Sciences, Islamic Republic of Iran, 1996
Several nonpeptide small molecules were designed as potential inhibitors of HIV protease and their structures were constructed by computer-aided molecular modeling and docked iwo the active site of HIV protease.
doaj  

ESTUDO COMPARATIVO DE DOCKING MOLECULAR ENTRE O INIBIDOR DE PROTEASE SAQUINAVIR E O CAROTENOIDE BIXINA COMO POTENCIAL INIBIDOR DO VÍRUS HIV TIPO I (1HXB)

Revista Expressão Católica Saúde, 2018
Atualmente, dentre os inibidores de protease de HIV aprovados pela FDA, disponíveis comercialmente, destaca-se o Saquinavir, um fármaco indicado para o tratamento do HIV-1 com imunodeficiência avançada, juntamente com análogos de nucleosídeo ...
Jacilene Silva, Marcia Machado Marinho, José Elieudo da Silva, Emanuelle Machado Marinho, Emmanuel Silva Marinho   +4 more
doaj   +1 more source

Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières [PDF]

, 2008
OBJECTIVES: To describe the use of second-line protease-inhibitor regimens in Médecins Sans Frontières HIV programmes, and determine switch rates, clinical outcomes, and factors associated with survival.
Alexandra Calmy, Boyd, Braitstein, Calmy, Calmy, Chaiwarith, Colebunders, Daniel O'Brien, Ferradini, Gallant, Galárraga, Ivers, Laurent, Ledergerber, Mar Pujades-Rodríguez, Mocroft, Nicastri, Orrell, Pierre Humblet, Renaud-Théry, Srasuebkul, Sungkanuparph, Vasan, Vekemans, Walmsley   +24 more
core   +2 more sources